Artbio Inc. and 3B Pharmaceuticals GmbH have signed a worldwide, exclusive license and research agreement to develop an advanced preclinical stage first-in-class peptide α-radioligand therapy for the treatment of solid tumors.
Avidity Biosciences Inc. has announced two new precision cardiology development candidates targeting rare genetic cardiomyopathies. AOC-1086 targets phospholamban (PLN) cardiomyopathy and AOC-1072 targets protein kinase AMP-activated noncatalytic subunit γ2 (PRKAG2) syndrome.
At the BioFuture 2024 conference held in New York in November, Seema Kumar, the CEO of Cure, described women’s health as something that has been directed at the “bikini area.” That “bikini” bias extended to both diseases and their causes – women’s health covered the breasts and reproductive system, and its causes were hormonal. Both concepts are far too narrow.
It’s difficult to fathom that the health of half the world’s population is underserved. But it’s a hard truth. There are many conditions that disproportionately impact women. Other conditions and diseases affect women in different ways than men. Decades of research excluding women from clinical trials and investment decisions in male-dominated board rooms have ignored these facts. Though an increasing number of women are now managing investments and driving the research, it’s all still woefully behind. In BioWorld’s new report, Healing the health divide, we’ve highlighted the disparities.
More than two years since emerging from stealth, Vesalius Therapeutics Inc. signed its first major pharma deal with GSK plc. Worth up to $650 million and possibly more if an option is exercised, the multitarget alliance aims to discover and develop novel treatments for Parkinson’s disease and another neurodegenerative indication.
Flare Therapeutics Inc. will receive $70 million in cash up front from Roche Holding AG, and the deal could ultimately bring the company about $1.8 billion plus royalties. Flare will search for small molecules that can be used to treat undruggable transcription factors to treat cancer. Also, Novartis AG will pay computational-chemistry expert Schrödinger Inc. $150 million up front and as much as $2.3 billion in milestones to develop several candidates along with up to $892 million in R&D and milestone payments.
Shenzhen Salubris Pharmaceuticals Co. Ltd. has described tertiary amine compounds reported to be useful for the treatment of stroke, atherosclerosis, thrombosis, coronary heart disease and aortic valve stenosis.
Genosco Inc. has divulged Rho-associated protein kinase 2 (ROCK2) inhibitors reported to be useful for the treatment of fibrosis, cancer, cardiovascular and inflammatory disorders.
China Hinye Pharmaceutical Co. Ltd. has identified pyrrole sulfonyl compounds and deuterated derivatives acting as H+/K+-ATPase inhibitors reported to be useful for the treatment of peptic ulcers, Zollinger-Ellison syndrome, gastroesophageal reflux disease, dyspepsia, reflux esophagitis, Barrett esophagus, Helicobacter pylori infection and gastric cancer.
RSS
